Nasdaq (NDAQ) won regulatory approval to add Monday and Wednesday options expirations in certain stocks, according to a media report on Friday. “This decision supports greater flexibility and ...

Genesis HealthCare on Wednesday said it had chosen a newly entered bidder to buy its assets after a one-day auction. 101 West Street was selected as the buyer following five rounds of bidding, in ...

Merriam-Webster declared "slop" its 2025 word of the year on Monday, a sign of growing wariness around artificial intelligence. Slop is now defined as "digital content of low quality that is produced ...

The U.S. Securities and Exchange Commission (SEC) implicitly granted approval for some stocks and other securities to be tokenized and traded on blockchains. The Depository Trust & Clearing Corp.

For the past five years, the Black Lives Matter RI PAC has been active in Rhode Island, advocating for racial justice, police reform, and other policy changes following the killing of George Floyd.

PythoC lets you use Python as a C code generator, but with more features and flexibility than Cython provides. Here’s a first look at the new C code generator for Python. Python and C share more than ...

Anthropic is launching Claude Code in Slack, allowing developers to delegate coding tasks directly from chat threads. The beta feature, available Monday as a research preview, builds on Anthropic’s ...

COLUMBUS, Ga. (WRBL) — On Monday, the Columbus Clingstones announced a new game time for several weeknight home games for the 2026 season. In partnership with Visit Columbus, GA, 43 of the Clingstones ...

Python has become one of the most popular programming languages out there, particularly for beginners and those new to the hacker/maker world. Unfortunately, while it’s easy to get something up and ...

Christine has had an infatuation with video games since she was a child, starting with games such as Diablo 2 and Morrowind. Her current obsessions include Final Fantasy 14, Genshin Impact, and Dragon ...

As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its 13-year-old drug Perjeta is inching toward the end of its exclusive run in the U.S.